SeraNovo's Eutectic Formulation Exceeds ASD by 75% in Bioavailability


Insights from the Case Study of Atazanavir

Our formulation has achieved an impressive 75% higher bioavailability compared to traditional formulations. Download the full PDF to uncover the science behind our innovative formulation strategy.

This website uses cookies to track the usage of it.

More info